Effects of Probiotics on Health, 2nd Edition

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Food Microbiology".

Deadline for manuscript submissions: 31 May 2024 | Viewed by 1175

Special Issue Editor


E-Mail Website
Guest Editor
Katedra Mikrobiologii, Uniwersytet Jagielloński Collegium Medicum, Krakow, Poland
Interests: probiotics; postbiotics; human microbiome; mechanisms of infections; hospital infections
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

There are two convergent origins of the living organisms described now as probiotics. Historically, these were microorganisms safely consumed through fermented foods. Many of these bacteria were known as lactic acid producers and were able to inhibit the growth of other, mostly pathogenic, microorganisms. They were later considered as probiotics, which, according to their definition, act through diverse mechanisms to confer a health benefit to the host. However, the modern approach to probiotics has come from studies on microbiomes of the higher organisms and on the important role the microbiome plays in the integrity and functions of the host. The microbiome contributes to early life imprinting, particularly through its effects on the developing immune system. The members of the microbiome, soon after successful gut colonization, come into direct crosstalk with the epithelial cells of the body’ surfaces, inducing transcriptional changes in the epithelium that cause alterations in the expression of multiple genes. The microbiome plays an important role in the regulation of the immune response in the innate and mucosal immune systems and contributes to colonization resistance in different niches of the host. All these properties have led to the idea that the microbiome is distorted in many conditions and diseases, and can be restored by administering beneficial microorganisms isolated from a healthy microbiome. These were originally represented by the Lactobacillus and Bifidobacterium genera. The availability of whole-genome sequencing and the era of genomics have enabled the mechanisms of probiotic efficacy to be elucidated and have facilitated the discovery and characterization of new strains of microorganisms with probiotic properties among those residing in the microbiome. This novel and inquisitive look at these bacteria has resulted in an enormous wave of research and extensive developments in the prospective field of probiotics. It appears that probiotics will soon be useful not only in correcting distorted microbiota, but also in facilitating and directing the development of the microbiota in human and animal newborns. Because microorganisms of the healthy microbiome with probiotic properties have been increasingly described and characterized in recent years, the original list, which originally comprised several probiotic strains belonging to a few species, has been lengthened to hundreds and is growing prospectively. The mechanisms by which probiotic microorganisms positively interact with host organisms has appeared to be not exclusively linked to viable cells and has generated a new field of postbiotics, i.e., non-viable bacterial cells, their components and metabolites, which present the majority of probiotic properties. Since postbiotics share many health-promoting activities with probiotics but possess a more extensive applicative potential, it is expected that they will stimulate a wide range of research on their characteristics and mechanisms of action in various hosts.

This Special Issue aims to gather original publications and reviews on probiotics and postbiotics from all fields of research based on in vitro and in vivo studies.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following fields: medicine, veterinary medicine, food (human and animal), vertebrate and non-vertebrate biology; the effects of the environment on their taxonomy, genetics, metabolism, functionality; and the effects exerted on host organisms: position in microbiome and microbiota, interactions with other microorganisms and the crosstalk with host cells, including immune-competent cells, and the effects on innate immunity mechanisms.

I look forward to receiving your contributions.

Prof. Dr. Piotr B. Heczko
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • probiotics
  • postbiotics
  • taxonomy
  • genomics
  • proteomics
  • metabolomics
  • microbiome
  • immunity
  • tissue
  • animals

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research

3 pages, 170 KiB  
Editorial
Editorial for Special Issue “Effects of Probiotics on Health”
by Piotr Heczko
Microorganisms 2024, 12(3), 442; https://doi.org/10.3390/microorganisms12030442 - 22 Feb 2024
Viewed by 657
Abstract
Since 1987, when Professor Sherwood Gorbach discovered, characterized, and commercialized the first probiotic Lactobacillus rhamnosus GG, a total of over 17,000 publications have been indexed in PubMed under “probiotic” and “health”, which is an extensive amount of research on the specific bacteria [...] Read more.
Since 1987, when Professor Sherwood Gorbach discovered, characterized, and commercialized the first probiotic Lactobacillus rhamnosus GG, a total of over 17,000 publications have been indexed in PubMed under “probiotic” and “health”, which is an extensive amount of research on the specific bacteria and yeasts defined as “live microorganisms that, when administered in adequate amounts, exert a health benefit on the host” [...] Full article
(This article belongs to the Special Issue Effects of Probiotics on Health, 2nd Edition)

Research

Jump to: Editorial

13 pages, 655 KiB  
Article
Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 Versus Placebo as Prophylaxis for Recurrence of Urinary Tract Infections in Children
by Maria Daniel, Hanna Szymanik-Grzelak, Janusz Sierdziński and Małgorzata Pańczyk-Tomaszewska
Microorganisms 2024, 12(6), 1037; https://doi.org/10.3390/microorganisms12061037 - 21 May 2024
Viewed by 186
Abstract
Urinary tract infections (UTIs) rank among the most prevalent bacterial infections in children. Probiotics appear to reduce the risk of recurrence of UTIs. This study aimed to evaluate whether probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 therapy prevent UTIs in the [...] Read more.
Urinary tract infections (UTIs) rank among the most prevalent bacterial infections in children. Probiotics appear to reduce the risk of recurrence of UTIs. This study aimed to evaluate whether probiotics containing Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 therapy prevent UTIs in the pediatric population compared to a placebo. A superiority, double-blind, randomized, controlled trial was conducted. In total, 54 children aged 3–18 years with recurrent UTIs or ≥one acute pyelonephritis and ≥one risk factor of recurrence of UTIs were randomly assigned (27 patients in each arm) to a 90-day probiotic or placebo arm. The age, sex, diagnosis, renal function, risk factors, and etiology of UTIs did not vary between the groups. During the intervention, 26% of children taking the probiotic had episodes of UTI, and it was not significantly less than in the placebo group. The number of UTI episodes during the intervention and the follow-up period decreased significantly in both groups, but the difference between them was insignificant. We observed a decrease in UTIs during the study of almost 50% in the probiotic group compared to the placebo group. Probiotics can be used as natural, safe prophylaxis for children with risk factors for UTIs in whom antibiotic prevention is not indicated. Full article
(This article belongs to the Special Issue Effects of Probiotics on Health, 2nd Edition)
Back to TopTop